1. AstraZeneca and Bristol-Myers Squibb

Who: AstraZeneca 
With: Bristol-Myers Squibb
What: $1.05 billion collaboration

Summary: In an unusual partnership between drug giants, AstraZeneca agreed to pay Bristol-Myers Squibb $100 million up front and up to $950 million more in milestones to partner up on two new drugs for the hot diabetes market. AstraZeneca has also agreed to take on 75 percent of the development costs of both late-stage compounds, saxagliptin and dapagliflozin. The companies will split global sales and revenue on both products. Release

Related Articles:
BMS unveils positive diabetes data. Report
AstraZeneca, BMS ink billion-dollar pact on diabetes drugs. Report

1. AstraZeneca and Bristol-Myers Squibb
Read more on

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.